Matthew L.  Posard net worth and biography

Matthew Posard Biography and Net Worth

Mr. Posard previously served as President and Chief Commercial Officer of GenePeaks, Inc., a computational genomics company, Executive Vice President, Chief Commercial Officer of Trovagene, where he oversaw sales, marketing, client services, market and business development, and Senior Vice President and General Manager of Illumina’s New Emerging Opportunity Business, where he oversaw the development and transfer of Illumina technology into new markets. He joined Illumina in 2006 as Vice President of Global Marketing and served as Vice President of Global Sales from 2007 to 2011, leading Illumina’s successful commercial entry into the life science sequencing market. Prior to joining Illumina, Mr. Posard held various positions in strategic and product marketing at Gen-Probe, Inc., helping the company attain leading market positions in DNA probe-based infectious disease diagnostics and blood banking. Previously, he oversaw global marketing at Biosite, Inc., where he was instrumental in the successful introduction of the company’s BNP congestive heart failure biomarker and its BNP co-marketing collaboration with Beckman Coulter. He currently serves on the Board of Directors of DermTech, Inc, Nautilus Biotechnology, Inc. and Talis Biomedical Corporation. Mr. Posard holds a B.A. degree in Quantitative Economics and Decision Science from the University of California, San Diego. He is a member of the Audit Committee and is the Chair of the Nominating and Corporate Governance Committee.

What is Matthew L. Posard's net worth?

The estimated net worth of Matthew L. Posard is at least $283,364.94 as of December 5th, 2022. Mr. Posard owns 115,189 shares of Nautilus Biotechnology stock worth more than $283,365 as of April 20th. This net worth estimate does not reflect any other assets that Mr. Posard may own. Learn More about Matthew L. Posard's net worth.

How do I contact Matthew L. Posard?

The corporate mailing address for Mr. Posard and other Nautilus Biotechnology executives is 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003. Nautilus Biotechnology can also be reached via phone at 206-333-2001 and via email at [email protected]. Learn More on Matthew L. Posard's contact information.

Has Matthew L. Posard been buying or selling shares of Nautilus Biotechnology?

Matthew L. Posard has not been actively trading shares of Nautilus Biotechnology in the last ninety days. Most recently, on Tuesday, November 30th, Matthew L. Posard bought 20,000 shares of Nautilus Biotechnology stock. The stock was acquired at an average cost of $4.57 per share, with a total value of $91,400.00. Learn More on Matthew L. Posard's trading history.

Who are Nautilus Biotechnology's active insiders?

Nautilus Biotechnology's insider roster includes Matthew Mcilwain (Director), Anna Mowry (CFO), Matthew Murphy (General Counsel), Sujal Patel (CEO), and Matthew Posard (Director). Learn More on Nautilus Biotechnology's active insiders.

Are insiders buying or selling shares of Nautilus Biotechnology?

In the last year, Nautilus Biotechnology insiders bought shares 3 times. They purchased a total of 38,303 shares worth more than $108,316.27. The most recent insider tranaction occured on March, 11th when CEO Sujal M Patel bought 12,044 shares worth more than $34,204.96. Insiders at Nautilus Biotechnology own 42.5% of the company. Learn More about insider trades at Nautilus Biotechnology.

Information on this page was last updated on 3/11/2024.

Matthew L. Posard Insider Trading History at Nautilus Biotechnology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/30/2021Buy20,000$4.57$91,400.00View SEC Filing Icon  
See Full Table

Matthew L. Posard Buying and Selling Activity at Nautilus Biotechnology

This chart shows Matthew L Posard's buying and selling at Nautilus Biotechnology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Nautilus Biotechnology Company Overview

Nautilus Biotechnology logo
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $2.46
Low: $2.31
High: $2.46

50 Day Range

MA: $2.70
Low: $2.34
High: $3.06

2 Week Range

Now: $2.46
Low: $2.16
High: $4.65

Volume

52,503 shs

Average Volume

79,976 shs

Market Capitalization

$307.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2